This is mainly because BTK and BCL2 inhibitors have been demonstrated to markedly improve progression-free and overall survival (PFS and OS) in TP53-deficient and IGHV unmutated CLL patients (4, 5, 7, 9, 10, 14, 23–25). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.